Hormone receptor (HR) positive and HER2 negative (HR+/HER2−) was the most common subtype among the MBC patients in both cohorts A and B followed by the HER2-positive and triple-negative breast cancer (TNBC) subtypes. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.